Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Arkaitz Carracedo, Li Ma, Julie Teruya‐Feldstein et al. · Journal of Clinical Investigation · 2008 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +17

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Jeffrey A. Engelman, Liang Chen, Xiaohong Tan et al. · Nature Medicine · 2008 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Violeta Serra, Maurizio Scaltriti, Ludmila Prudkin et al. · Oncogene · 2011 · 534 citations · Full text

Medicine, Cancer Biology, Pharmacology +17

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

Josep Tabernero, Federico Rojo, Emiliano Calvo et al. · Journal of Clinical Oncology · 2008 · 532 citations

Medicine, Oncology, Pharmacology +17